Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund lessened its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.6% during the first quarter, HoldingsChannel reports. The firm owned 23,602 shares of the biopharmaceutical company’s stock after selling 619 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Alexion Pharmaceuticals were worth $3,191,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ALXN. Investors Research Corp bought a new position in Alexion Pharmaceuticals in the 1st quarter valued at about $27,000. Captrust Financial Advisors bought a new position in shares of Alexion Pharmaceuticals during the 4th quarter worth approximately $31,000. NuWave Investment Management LLC lifted its position in shares of Alexion Pharmaceuticals by 851.9% during the 4th quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 460 shares in the last quarter. Kaizen Advisory LLC lifted its position in shares of Alexion Pharmaceuticals by 22.2% during the 4th quarter. Kaizen Advisory LLC now owns 610 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 111 shares in the last quarter. Finally, Whittier Trust Co. lifted its position in shares of Alexion Pharmaceuticals by 20.4% during the 1st quarter. Whittier Trust Co. now owns 472 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 80 shares in the last quarter. 97.89% of the stock is currently owned by institutional investors.

Shares of ALXN stock opened at $127.55 on Thursday. The company has a quick ratio of 3.36, a current ratio of 3.87 and a debt-to-equity ratio of 0.25. Alexion Pharmaceuticals, Inc. has a 12-month low of $92.56 and a 12-month high of $141.86. The company has a market cap of $28.88 billion, a PE ratio of 17.99, a P/E/G ratio of 1.01 and a beta of 1.53.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.99 by $0.40. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the business posted $1.68 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 22.5% compared to the same quarter last year. Equities analysts forecast that Alexion Pharmaceuticals, Inc. will post 8.6 earnings per share for the current fiscal year.

ALXN has been the topic of several recent analyst reports. Cowen reissued a “buy” rating and set a $165.00 target price on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 13th. Raymond James lifted their target price on shares of Alexion Pharmaceuticals from $161.00 to $164.00 and gave the stock an “outperform” rating in a research report on Friday, April 26th. Morgan Stanley lifted their target price on shares of Alexion Pharmaceuticals from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 12th. Guggenheim reissued a “neutral” rating and set a $135.00 target price on shares of Alexion Pharmaceuticals in a research report on Thursday, March 21st. Finally, BidaskClub raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $163.06.

COPYRIGHT VIOLATION NOTICE: This article was originally published by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.wkrb13.com/2019/05/23/alexion-pharmaceuticals-inc-alxn-shares-sold-by-oregon-public-employees-retirement-fund.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: What causes a recession?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.